Literature DB >> 23563310

Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.

Hua Zhang1, A S Verkman.   

Abstract

Eosinophils are abundant in inflammatory demyelinating lesions in neuromyelitis optica (NMO). We used cell culture, ex vivo spinal cord slices, and in vivo mouse models of NMO to investigate the role of eosinophils in NMO pathogenesis and the therapeutic potential of eosinophil inhibitors. Eosinophils cultured from mouse bone marrow produced antibody-dependent cell-mediated cytotoxicity (ADCC) in cell cultures expressing aquaporin-4 in the presence of NMO autoantibody (NMO-IgG). In the presence of complement, eosinophils greatly increased cell killing by a complement-dependent cell-mediated cytotoxicity (CDCC) mechanism. NMO pathology was produced in NMO-IgG-treated spinal cord slice cultures by inclusion of eosinophils or their granule toxins. The second-generation antihistamines cetirizine and ketotifen, which have eosinophil-stabilizing actions, greatly reduced NMO-IgG/eosinophil-dependent cytotoxicity and NMO pathology. In live mice, demyelinating NMO lesions produced by continuous intracerebral injection of NMO-IgG and complement showed marked eosinophil infiltration. Lesion severity was increased in transgenic hypereosinophilic mice. Lesion severity was reduced in mice made hypoeosinophilic by anti-IL-5 antibody or by gene deletion, and in normal mice receiving cetirizine orally. Our results implicate the involvement of eosinophils in NMO pathogenesis by ADCC and CDCC mechanisms and suggest the therapeutic utility of approved eosinophil-stabilizing drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23563310      PMCID: PMC3635742          DOI: 10.1172/JCI67554

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

Review 1.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

2.  Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays.

Authors:  Jonathan M Crane; Chiwah Lam; Andrea Rossi; Tripta Gupta; Jeffrey L Bennett; A S Verkman
Journal:  J Biol Chem       Date:  2011-03-21       Impact factor: 5.157

3.  Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.

Authors:  Pascale Hubert; Adèle Heitzmann; Sophie Viel; André Nicolas; Xavier Sastre-Garau; Pablo Oppezzo; Otto Pritsch; Eduardo Osinaga; Sebastian Amigorena
Journal:  Cancer Res       Date:  2011-06-22       Impact factor: 12.701

4.  Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.

Authors:  Julien Ratelade; Hua Zhang; Samira Saadoun; Jeffrey L Bennett; Marios C Papadopoulos; A S Verkman
Journal:  Acta Neuropathol       Date:  2012-04-22       Impact factor: 17.088

5.  Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice.

Authors:  Tomohiro Yamada; Yukako Tani; Hiroki Nakanishi; Ryo Taguchi; Makoto Arita; Hiroyuki Arai
Journal:  FASEB J       Date:  2010-10-19       Impact factor: 5.191

6.  Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence.

Authors:  Anu Jacob; Samira Saadoun; Joanna Kitley; Maria Leite; Jacqueline Palace; Frederick Schon; Marios C Papadopoulos
Journal:  Mult Scler       Date:  2012-04-11       Impact factor: 6.312

Review 7.  Targeting eosinophils in allergy, inflammation and beyond.

Authors:  Patricia C Fulkerson; Marc E Rothenberg
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

Review 8.  Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.

Authors:  Sven Jarius; Friedemann Paul; Diego Franciotta; Patrick Waters; Frauke Zipp; Reinhard Hohlfeld; Angela Vincent; Brigitte Wildemann
Journal:  Nat Clin Pract Neurol       Date:  2008-03-11

9.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

10.  A study of the Interaction Between Cetirizine and Plasma Membrane of Eosinophils, Neutrophils, Platelets and Lymphocytes using A fluorescence Technique.

Authors:  A Kantar; N Oggiano; P L Giorgi; J P Rihoux
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

View more
  57 in total

1.  Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.

Authors:  Julien Ratelade; Nithi Asavapanumas; Alanna M Ritchie; Scott Wemlinger; Jeffrey L Bennett; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

2.  Noninvasive, Targeted Creation of Neuromyelitis Optica Pathology in AQP4-IgG Seropositive Rats by Pulsed Focused Ultrasound.

Authors:  Xiaoming Yao; Matthew S Adams; Peter D Jones; Chris J Diederich; Alan S Verkman
Journal:  J Neuropathol Exp Neurol       Date:  2019-01-01       Impact factor: 3.685

Review 3.  Emerging therapeutic targets for neuromyelitis optica spectrum disorder.

Authors:  Lukmanee Tradtrantip; Nithi Asavapanumas; Alan S Verkman
Journal:  Expert Opin Ther Targets       Date:  2020-03-02       Impact factor: 6.902

4.  Optic neuritis in neuromyelitis optica.

Authors:  Marc H Levin; Jeffrey L Bennett; A S Verkman
Journal:  Prog Retin Eye Res       Date:  2013-03-30       Impact factor: 21.198

5.  Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.

Authors:  Julien Ratelade; Alex J Smith; A S Verkman
Journal:  Exp Neurol       Date:  2014-03-14       Impact factor: 5.330

Review 6.  Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.

Authors:  A S Verkman; Puay-Wah Phuan; Nithi Asavapanumas; Lukmanee Tradtrantip
Journal:  Brain Pathol       Date:  2013-11       Impact factor: 6.508

Review 7.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

8.  Inhibitor(s) of the classical complement pathway in mouse serum limit the utility of mice as experimental models of neuromyelitis optica.

Authors:  Julien Ratelade; A S Verkman
Journal:  Mol Immunol       Date:  2014-06-28       Impact factor: 4.407

9.  Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration.

Authors:  Anne Winkler; Claudia Wrzos; Michael Haberl; Marie-Theres Weil; Ming Gao; Wiebke Möbius; Francesca Odoardi; Dietmar R Thal; Mayland Chang; Ghislain Opdenakker; Jeffrey L Bennett; Stefan Nessler; Christine Stadelmann
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

10.  Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions.

Authors:  Claudia Wrzos; Anne Winkler; Imke Metz; Dieter M Kayser; Dietmar R Thal; Christiane Wegner; Wolfgang Brück; Stefan Nessler; Jeffrey L Bennett; Christine Stadelmann
Journal:  Acta Neuropathol       Date:  2013-11-30       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.